The Valley Desk

NCT04214067 · Interventional trial

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Overall registry status Active not recruiting

Phase 3

Conditions Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov